Launch of Biopharma SHAKTI Scheme
Why focus: GS3 Sci-Tech: Flagship scheme launch with numeric targets. Tests biosimilars vs biologics concepts and 'How-Many-Correct' on budget outlays.
In News
What Happened
Why It Matters
Background
History & Context
What Changed
- ▶
BEFORE: Funding for biologics research was fragmented and insufficient for large-scale scaling. NOW: A dedicated Rs. 10,000 crore outlay over five years specifically targets an end-to-end biologics and biosimilars ecosystem.
- ▶
BEFORE: Preclinical drug trials relied heavily on traditional in-vivo animal testing. NOW: The scheme prioritises a shift to Non-Animal Methodologies (NAMs) such as organoids and organ-on-a-chip technologies.
- ▶
BEFORE: Clinical trials faced delays due to a lack of standardised, ready-to-use testing sites. NOW: The scheme mandates the creation of a national network comprising over 1,000 accredited clinical trial sites.
- ▶
BEFORE: National Institutes of Pharmaceutical Education and Research (NIPERs) focused on broad pharmaceutical education. NOW: These institutes will play a specialised role in training a workforce for complex biologics manufacturing and NAMs.
- ▶
BEFORE: India captured only a small fraction of the global biosimilars market. NOW: Targeted ecosystem support aims to replicate India's generic drug success in the high-value biosimilars segment.
What Did NOT Change
The overarching regulatory authority remains with the Central Drugs Standard Control Organisation (CDSCO), and standard clinical trial phases (Phases I-IV) still apply. Furthermore, traditional animal testing is not completely banned; NAMs are prioritised and incentivised, but not made exclusively mandatory for all drug classes immediately.
Prelims Angle
NCERT Connection
Common Misconceptions
✗ Biosimilars are exactly identical to their reference biologic drugs, just like generic drugs are to chemical drugs.
✓ Unlike generic chemical drugs, biosimilars are highly similar but not perfectly identical to their reference biologics due to the natural variability of living biological systems used to produce them.
People conflate simple chemical synthesis (which produces exact molecular copies) with biological manufacturing (where host cells inevitably introduce slight, clinically insignificant variations).
✗ Non-Animal Methodologies (NAMs) mean that drugs are tested directly on humans after running computer simulations.
✓ NAMs heavily involve advanced in-vitro biological models like organ-on-a-chip and 3D organoids derived from human stem cells, which mimic human organ function without using living animals.
The term 'non-animal' leads people to think of purely digital (in-silico) models, ignoring the massive biological advancements in human tissue engineering.
Practice Questions
Q1
How Many CorrectConsider the following statements regarding the Biopharma SHAKTI scheme: 1. It aims to completely ban traditional animal testing for all preclinical trials in India by 2027. 2. The scheme supports the production of biosimilars, which are exact identical copies of reference biologics. 3. It proposes the establishment of a national network of over 1,000 accredited clinical trial sites. How many of the above statements are correct?
Q2
Match the FollowingMatch List I (Biopharma Terminology) with List II (Description): List I: A. Organoids B. Biosimilars C. Generic Drugs D. Organ-on-a-chip List II: 1. Microfluidic devices lined with living human cells to simulate organ level physiology 2. Exact chemical copies of small-molecule reference drugs 3. Highly similar clinical equivalents of complex biological drugs 4. 3D miniaturised and simplified versions of organs produced in vitro Select the correct answer:
Q3
Assertion & ReasonAssertion (A): The Biopharma SHAKTI scheme focuses on transitioning from traditional in-vivo animal testing to Non-Animal Methodologies (NAMs) like organoids. Reason (R): Animal models often fail to accurately predict human responses to complex biologics, leading to high failure rates in human clinical trials. Select the correct answer: